La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the “Company” or “La Jolla”), a biotechnology company developing therapeutics targeting significant unmet, life-threatening diseases today announced that George Tidmarsh, MD, PhD, President and CEO of La Jolla will be presenting a corporate update at the 26th Annual ROTH Conference on March 10, 2014 at 2:30 PM pacific time. An update on the phase 2 clinical study of GCS-100 for the treatment of chronic kidney disease will be included in the presentation.
Help employers find you! Check out all the jobs and post your resume.
